Silencing Circ_0000644 Inhibits Papillary Thyroid Cancer Cell Malignancy by Combining with MiR-671-5p to Release the Inhibition on ANXA2

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2022 Oct 12

PMID 36224454

Authors

Hong-Guang Li

Li-Hong Zhao

Jun-Zhao Liu

Kun-Peng Liu

Jian-Bo Liu

Zi-Jie Su

Yong-Ju Gao

Affiliations

Soon will be listed here.

Abstract

Background: Papillary thyroid cancer (PTC) is life-threatening due to its malignant progression. Considerable evidence demonstrates that circular RNA (circRNA) regulates PTC development. This study aims to explore the mechanism of circ_0000644 modulating PTC malignant progression.

Methods: The RNA levels of circ_0000644, microRNA-671-5p (miR-671-5p) and annexin A2 (ANXA2) were detected by quantitative real-time polymerase chain reaction. Western blot was performed to check protein expression. Cell proliferation and cell apoptosis were investigated by 5-ethynyl-29-deoxyuridine and flow cytometry. Angiogenic capacity, migration and invasion were analyzed by tube formation assay and transwell assay. The interaction between miR-671-5p and circ_0000644 or ANXA2 was identified by dual-luciferase reporter assay. Xenograft mouse model assay was performed to analyze the effect of circ_0000644 on tumor formation in vivo.

Results: Circ_0000644 and ANXA2 expression was significantly upregulated, while miR-671-5p was downregulated in PTC tissues and cells when compared with control groups. Circ_0000644 knockdown inhibited PTC cell proliferation, tube formation, migration, and invasion, but induced apoptosis in vitro. Moreover, circ_0000644 knockdown led to delayed tumorigenesis in vivo. In addition, circ_0000644 acted as a miR-671-5p sponge and mediated PTC cell tumor properties through miR-671-5p. ANXA2 was identified as a target gene of miR-671-5p, and its overexpression relieved miR-671-5p-induced effects in PTC cells. Furthermore, circ_0000644 depletion inhibited ANXA2 production by combining with miR-671-5p.

Conclusion: Circ_0000644 depletion repressed PTC cell tumor properties through the miR-671-5p/ANXA2 axis.

Citing Articles

High aggressiveness of papillary thyroid cancer: from clinical evidence to regulatory cellular networks.

Zhang J, Xu S Cell Death Discov. 2024; 10(1):378.

PMID: 39187514 PMC: 11347646. DOI: 10.1038/s41420-024-02157-2.

The emerging role and clinical significance of circRNAs in papillary thyroid cancer.

Ma J, Xu J, Zhang X, Quan J Front Endocrinol (Lausanne). 2024; 15:1351776.

PMID: 38544689 PMC: 10965563. DOI: 10.3389/fendo.2024.1351776.

References

Kitahara C, Sosa J . The changing incidence of thyroid cancer. Nat Rev Endocrinol. 2016; 12(11):646-653. PMC: 10311569. DOI: 10.1038/nrendo.2016.110. View

Clark O . Thyroid cancer and lymph node metastases. J Surg Oncol. 2011; 103(6):615-8. DOI: 10.1002/jso.21804. View

Clarke C, Reynolds P, Oakley-Girvan I, Lee E, Lu Y, Yang J . Indicators of microbial-rich environments and the development of papillary thyroid cancer in the California Teachers Study. Cancer Epidemiol. 2015; 39(4):548-53. PMC: 4532633. DOI: 10.1016/j.canep.2015.04.014. View

Guo M, Sun Y, Ding J, Li Y, Yang S, Zhao Y . Circular RNA profiling reveals a potential role of hsa_circ_IPCEF1 in papillary thyroid carcinoma. Mol Med Rep. 2021; 24(2). PMC: 8240180. DOI: 10.3892/mmr.2021.12241. View

Wang P, Bao Y, Yee M, Barrett S, Hogan G, Olsen M . Circular RNA is expressed across the eukaryotic tree of life. PLoS One. 2014; 9(6):e90859. PMC: 3946582. DOI: 10.1371/journal.pone.0090859. View

Jeck W, Sharpless N . Detecting and characterizing circular RNAs. Nat Biotechnol. 2014; 32(5):453-61. PMC: 4121655. DOI: 10.1038/nbt.2890. View

Thomson D, Dinger M . Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet. 2016; 17(5):272-83. DOI: 10.1038/nrg.2016.20. View

Kristensen L, Andersen M, Stagsted L, Ebbesen K, Hansen T, Kjems J . The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019; 20(11):675-691. DOI: 10.1038/s41576-019-0158-7. View

Bach D, Lee S, Sood A . Circular RNAs in Cancer. Mol Ther Nucleic Acids. 2019; 16:118-129. PMC: 6411617. DOI: 10.1016/j.omtn.2019.02.005. View

10.

Lou W, Ding B, Wang J, Xu Y . The Involvement of the hsa_circ_0088494-miR-876-3p-CTNNB1/CCND1 Axis in Carcinogenesis and Progression of Papillary Thyroid Carcinoma. Front Cell Dev Biol. 2020; 8:605940. PMC: 7755655. DOI: 10.3389/fcell.2020.605940. View

11.

Wen X, Du J, Wang X . Circ_0039411 promotes papillary thyroid carcinoma development through mediating the miR-423-5p/SOX4 signaling. Int J Biol Markers. 2021; 36(4):10-20. DOI: 10.1177/17246008211043128. View

12.

Yao Y, Chen X, Yang H, Chen W, Qian Y, Yan Z . Hsa_circ_0058124 promotes papillary thyroid cancer tumorigenesis and invasiveness through the NOTCH3/GATAD2A axis. J Exp Clin Cancer Res. 2019; 38(1):318. PMC: 6642504. DOI: 10.1186/s13046-019-1321-x. View

13.

Nie C, Han J, Bi W, Qiu Z, Chen L, Yu J . Circular RNA circ_0000644 promotes papillary thyroid cancer progression via sponging miR-1205 and regulating E2F3 expression. Cell Cycle. 2021; 21(2):126-139. PMC: 8837259. DOI: 10.1080/15384101.2021.2012334. View

14.

Farazi T, Spitzer J, Morozov P, Tuschl T . miRNAs in human cancer. J Pathol. 2010; 223(2):102-15. PMC: 3069496. DOI: 10.1002/path.2806. View

15.

Zembska A, Jawiarczyk-Przybylowska A, Wojtczak B, Bolanowski M . MicroRNA Expression in the Progression and Aggressiveness of Papillary Thyroid Carcinoma. Anticancer Res. 2018; 39(1):33-40. DOI: 10.21873/anticanres.13077. View

16.

Yu S, Cao S, Hong S, Lin X, Guan H, Chen S . miR-3619-3p promotes papillary thyroid carcinoma progression via Wnt/β-catenin pathway. Ann Transl Med. 2020; 7(22):643. PMC: 6944574. DOI: 10.21037/atm.2019.10.71. View

17.

Wang W, Yuan Y, Zhang D, Liu P, Liu F . miR-671-5p repressed progression of papillary thyroid carcinoma via TRIM14. Kaohsiung J Med Sci. 2021; 37(11):983-990. DOI: 10.1002/kjm2.12424. View

18.

Rong D, Sun H, Li Z, Liu S, Dong C, Fu K . An emerging function of circRNA-miRNAs-mRNA axis in human diseases. Oncotarget. 2017; 8(42):73271-73281. PMC: 5641211. DOI: 10.18632/oncotarget.19154. View

19.

He Q, Zhao L, Liu X, Zheng J, Liu Y, Liu L . MOV10 binding circ-DICER1 regulates the angiogenesis of glioma via miR-103a-3p/miR-382-5p mediated ZIC4 expression change. J Exp Clin Cancer Res. 2019; 38(1):9. PMC: 6323715. DOI: 10.1186/s13046-018-0990-1. View

20.

Huang D, Huang M, Lin X, Huang Q . CD155 expression and its correlation with clinicopathologic characteristics, angiogenesis, and prognosis in human cholangiocarcinoma. Onco Targets Ther. 2017; 10:3817-3825. PMC: 5546808. DOI: 10.2147/OTT.S141476. View